Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Brain Metastases|HER2-positive Breast Cancer
Interventions: COMBINATION_PRODUCT: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Sponsor: Baptist Health South Florida
Collaborators: Seagen Inc.